According to Zacks, “Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts. “
Several other analysts also recently weighed in on the company. HC Wainwright cut their target price on Conatus Pharmaceuticals from $14.00 to $8.00 and set a buy rating on the stock in a research note on Monday, March 11th. Canaccord Genuity raised Nuvista Energy to a buy rating in a research note on Tuesday, April 9th. Finally, William Blair reaffirmed an outperform rating on shares of Aileron Therapeutics in a research note on Monday, May 6th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $4.33.
Aileron Therapeutics (NASDAQ:ALRN) last announced its earnings results on Wednesday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.13). On average, research analysts forecast that Aileron Therapeutics will post -1.11 EPS for the current fiscal year.
A hedge fund recently raised its stake in Aileron Therapeutics stock. Jennison Associates LLC lifted its position in Aileron Therapeutics Inc (NASDAQ:ALRN) by 649.6% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,040,255 shares of the company’s stock after buying an additional 1,768,073 shares during the period. Jennison Associates LLC owned approximately 13.72% of Aileron Therapeutics worth $3,828,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 29.17% of the company’s stock.
About Aileron Therapeutics
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Featured Article: What does RSI mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.